The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of Salivary Cortisol Hypertension Assay

18 Dec 2015 09:43

RNS Number : 5543J
Immunodiagnostic Systems Hldgs PLC
18 December 2015
 

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

18 December 2015

 

Immunodiagnostic Systems Holdings plc.

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, has launched the IDS-iSYS Salivary Cortisol assay in the European market - a fully automated assay for use with the IDS-iSYS Automated System.

The launch of the IDS-iSYS Salivary Cortisol assay enhances the IDS Hypertension panel, which also includes the automated IDS-iSYS Aldosterone and IDS-iSYS Direct Renin immunoassays.

The IDS-iSYS Salivary Cortisol assay measures a patient's salivary cortisol and offers clinicians an easy, non-invasive way to diagnose diseases of cortisol imbalance such as Cushing's Syndrome (CS). One sign of CS is a higher than expected level of cortisol, which can often lead to hypertension.

As the fastest salivary cortisol automated test on the market the IDS-iSYS Salivary Cortisol assay allows laboratories to benefit from a reduced time to first result.

The global market size of salivary cortisol testing is estimated to be around £5 - £10 million.

For further information:

Immunodiagnostic Systems Holdings plc Telephone: +44(0)191 519 0660Patricio Lacalle, CEOJaap Stuut, Marketing DirectorPeel Hunt LLP Telephone: +44(0)207 418 8900James Steel

 

About Immunodiagnostic Systems Holdings plc.:A Specialist in Endocrinology TestingImmunodiagnostic Systems Holdings plc (IDS) is a leading in vitro diagnostic solution provider to the clinical laboratory market. IDS develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. The IDS immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields.

IDS was founded in 1977 and trades on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange.IDS is a global company headquartered in the UK with around 400 employees worldwide. The group's products are developed and manufactured at their facilities in Europe. IDS serve customers through regional offices in Europe, U.S.A. and Brazil. The group's network of distributors work on IDS' behalf to serve customers throughout the rest of the world.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGCBDDDSBBGUI
Date   Source Headline
1st Jun 20117:00 amRNSAppointment of Non-Executive Director
9th May 20117:00 amRNSChange of contract terms
28th Apr 20117:00 amRNSTotal Voting Rights
12th Apr 20118:34 amRNSExercise of Share Options and Total Voting Rights
6th Apr 20117:00 amRNSTrading update
28th Mar 20117:35 amRNSExclusive Licence Agreement
1st Mar 20117:00 amRNSDirector/PDMR Shareholding
3rd Feb 201110:34 amRNSDirector/PDMR Shareholding
11th Jan 20113:40 pmRNSDirector/PDMR Shareholding
30th Nov 20107:00 amRNSHalf Yearly Report
12th Nov 20104:41 pmRNSSecond Price Monitoring Extn
12th Nov 20104:35 pmRNSPrice Monitoring Extension
1st Nov 201011:22 amRNSHolding(s) in Company
5th Oct 20108:56 amRNSPosting of Report and Accounts and Notice of AGM
5th Oct 20107:00 amRNSTrading Update
27th Sep 20107:00 amRNSIssue of Equity
21st Sep 20104:35 pmRNSPrice Monitoring Extension
20th Sep 201010:33 amRNSHolding(s) in Company
13th Sep 20107:00 amRNSAcquisition & Research Agreement
25th Aug 20104:06 pmRNSResult of AGM
25th Aug 20107:00 amRNSAGM Statement
26th Jul 20101:00 pmRNSExercise of Share Options and Total Voting Rights
26th Jul 20107:00 amRNSNew specialist assay launched for IDS-iSYS
20th Jul 20107:00 amRNSDirector/PDMR Shareholding
12th Jul 20107:00 amRNSDirectorate Change
12th Jul 20107:00 amRNSFinal Results
29th Jun 20107:00 amRNSReceipt of FDA 510(k) clearances
16th Jun 20104:40 pmRNSSecond Price Monitoring Extn
16th Jun 20104:35 pmRNSPrice Monitoring Extension
14th Jun 20104:35 pmRNSPrice Monitoring Extension
11th Jun 20104:35 pmRNSPrice Monitoring Extension
10th Jun 20104:35 pmRNSPrice Monitoring Extension
26th May 20104:40 pmRNSSecond Price Monitoring Extn
26th May 20104:35 pmRNSPrice Monitoring Extension
10th May 20107:00 amRNSExercise of Share Options
12th Apr 20107:00 amRNSTrading Statement
31st Mar 201012:24 pmRNSTotal Voting Rights
31st Mar 20107:00 amRNSNew specialist assays launched for IDS-iSYS
22nd Mar 20107:00 amRNSDirector/PDMR Shareholding
16th Mar 201010:00 amRNSDirector/PDMR Shareholding
23rd Feb 201011:47 amRNSExercise of Share Options
9th Feb 20107:00 amRNSShare options
1st Feb 20109:13 amRNSExercise of Share Options and Total Voting Rights
4th Jan 20107:00 amRNSFive year distribution agreement
21st Dec 20091:15 pmRNSDirector/PDMR Shareholding
18th Dec 20093:18 pmRNSIssue of Equity
11th Dec 20097:00 amRNSDirectorate Change
10th Dec 20097:00 amRNSExercise of Share Options and Directors' Dealings
30th Nov 20097:00 amRNSHalf Yearly Report
18th Nov 200910:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.